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Introduction
Type I IFNs (IFNα/β) promote the expression of antiviral mole-
cules in response to induction by several different transmem-
brane and cytosolic pattern recognition receptors (PRRs). Cellular 
responses to type I IFNs depend on binding to the heterodimeric 
receptor IFNAR, which initiates a signaling cascade that promotes 
nuclear translocation of STAT1/2 heterodimers and transcription-
al activation of IFN-stimulated genes (ISGs) (1). The rapid expres-
sion of hundreds of ISGs is critical for controlling viral infections, 
as these proteins block viral entry, translation, transcription, 
assembly, and egress (1–3). However, recent studies indicate that 
IFNAR signaling also regulates other pathways that impact cell- 
intrinsic antiviral functions. This is particularly evident in studies 
of IFNAR signaling by cellular constituents of the blood-brain bar-
rier (BBB) during neurotropic viral infection (4). The BBB, which 
protects the CNS from pathogens, is composed of specialized 
brain microvascular endothelial cells (BMECs) joined by tight 
junctions (TJs) and ensheathed by pericytes and astrocyte endfeet 
(5). While IFNAR signaling in both BMECs and astrocytes contrib-
utes to TJ integrity in vitro (4), the in vivo contribution of IFNAR 
signaling within astrocytes, which exhibit individual and regional 
heterogeneity, has not been explored.
Innate immune mechanisms that regulate BBB function in the 
setting of infectious diseases have been appreciated only recently. 
Multiple inflammatory cytokines, including TNF-α, IL-6, IL-1β, and 
IFN-γ, disrupt BBB and TJ integrity in BMECs through incomplete-
ly understood mechanisms (4, 6–8). Inflammatory cytokine signal-
ing at the BBB during infection facilitates leukocyte trafficking into 
the CNS, which is essential for clearance of many pathogens (9, 10). 
However, this process may have pathological consequences, as the 
CNS is susceptible to immune cell–mediated injury and possesses 
a limited capacity for repair (11). Moreover, increased BBB perme-
ability due to inflammatory cytokine signaling also may facilitate 
viral neuroinvasion (6). Thus, cytokine signaling in BBB constitu-
ent cells must be regulated to protect the CNS from infection and 
inflammation. In contrast to inflammatory cytokines, type I IFNs 
stabilize BBB integrity and enhance TJ formation via balanced 
activation of the small GTPases Rac1 and RhoA and by blocking 
expression of IL-1β, which induces barrier disruption (4). Through 
these actions, type I IFNs serve a protective function at the BBB by 
counterbalancing the effects of inflammatory cytokines.
Astrocytes have critical roles in host defense during viral 
infections of the CNS (12). PRR activation in astrocytes results in 
the expression of many immune mediators, including inflamma-
tory cytokines and type I IFNs (12, 13). During infection by patho-
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cerebellum (96.1%). Analysis of IFNAR expression on MAP2+ neu-
rons and IBA1+ microglia also revealed no significant deletion of 
Ifnar in these cell populations (Supplemental Figure 2, A and B). 
IFNAR antibody specificity was confirmed by stains using an iso-
type control antibody as well as tissue derived from Ifnar1–/– mice 
(Supplemental Figure 2C). We also observed similar levels of Cre 
recombinase expression in both cerebral cortex and cerebellum 
(Supplemental Figure 2D).
Following s.c. inoculation with 102 PFU of WNV (New York 
2000 strain), Ifnarfl/fl Gfap-Cre+ mice had accelerated and enhanced 
mortality (16.7% vs. 50.0% survival; Figure 1A) and greater clinical 
signs of disease (Figure 1B) compared with Ifnarfl/fl Cre– controls. In 
contrast, survival after WNV infection was unaffected in Ifnarfl/WT 
Gfap-Cre+ littermates or in congenic Gfap-Cre+ mice that had never 
been crossed with the Ifnarfl/fl line. As expected, viral burden did not 
differ in any peripheral tissue compartments analyzed, including 
serum, spleen, kidney, liver, and heart (Figure 1C and Supplemental 
Figure 3), while viral burden in the CNS was significantly higher in 
Ifnarfl/fl Gfap-Cre+ mice compared with Ifnarfl/fl Cre– controls. Virus 
was detected earlier in cerebellar tissues in Ifnarfl/fl Gfap-Cre+ mice 
on day 5 following infection (4 of 7 mice), when levels in Ifnarfl/fl 
Cre– controls were undetectable (Figure 1D). By day 6, viral burden 
in Ifnarfl/fl Gfap-Cre+ mice remained significantly higher in the cer-
ebellum, while titers in the cerebral cortex and brainstem were ele-
vated but did not reach statistical significance (P = 0.07 and 0.14, 
respectively). By day 8, viral burden was significantly increased in 
Ifnarfl/fl Gfap-Cre+ mice in all CNS regions analyzed, including the 
cerebral cortex, brainstem, and spinal cord (Figure 1, D–G).
The early appearance of virus within the cerebellum of Ifnarfl/fl 
Gfap-Cre+ mice suggested that astrocyte IFNAR signaling might 
limit neuroinvasion at this site. As previous studies have suggest-
ed that early WNV neuroinvasion can be caused by defects in BBB 
function (4, 27, 28), we determined whether BBB permeability 
was altered differentially in the cerebellum and cerebral cortex of 
Ifnarfl/fl Gfap-Cre+ mice compared with BBB permeability in Ifnarfl/fl 
Cre– littermate controls. Analysis of extravasation of sodium flu-
orescein (376 Da) on various days following s.c. infection showed 
biphasic kinetics, as observed in our previous studies (4, 21), with 
an enhancement of BBB permeability on day 4 after infection, 
decreased permeability on days 5 and 6, and a reopening of the BBB 
on day 8 (Figure 1H). While loss of IFNAR signaling in astrocytes led 
to enhancement of BBB permeability in both cerebral cortical and 
cerebellar tissues after infection, the kinetics of these effects dif-
fered between regions. In the cerebral cortex, genotype differences 
reached statistical significance only on days 6 and 8, whereas the 
ability of the BBB to close on day 5 after infection was attenuated 
significantly within the cerebellum (Figure 1H). Using immunohis-
tochemical detection of extravasated endogenous IgG (150 kDa), 
we observed enhanced BBB permeability to larger molecules on day 
6 in the cerebellum but not the cerebral cortex (Figure 1, I and J). 
The defect in BBB function on days 5 and 6 following infection coin-
cided with the early detection of virus in the cerebellum, suggesting 
that astrocyte IFNAR signaling in the cerebellum might be critical 
for regulating BBB responses that limit viral neuroinvasion.
Apart from its regulation of BBB function, IFN signaling in 
astrocytes may also serve protective antiviral functions for neurons 
(14, 29), which might contribute to higher CNS titers at early time 
gens for which glia are not permissive targets, activation due to 
pathogen recognition and/or abortive infection in astrocytes may 
also promote antiviral immune responses of permissive neurons 
as well as CNS leukocyte trafficking (6, 12, 14). Throughout the 
CNS, astrocytes exhibit individual and regional heterogeneity in 
gene expression, morphology, developmental ontogeny, and sig-
naling functions (15). Although in vitro studies have established 
the fact that astrocytes from different CNS regions respond 
differently to pathogenic stimuli (16, 17), the contributions of 
astrocyte heterogeneity to in vivo disease pathogenesis and host 
defense are unknown.
In this study, we investigated how IFNAR signaling in astro-
cytes impacts the neuropathogenesis of West Nile virus (WNV) 
encephalitis. Neurons are by far the preferred cellular target of 
WNV throughout the CNS (12, 18, 19); in contrast, infection of glial 
cells in vivo has not been well documented in mice and is proba-
bly rare (20). However, astrocyte activation and gliosis has been 
observed in vivo during WNV infection (9, 21). Given the findings 
from our own studies demonstrating that IFNAR signaling in astro-
cytes enhances in vitro BBB integrity in response to WNV (4), we 
used Ifnarfl/fl Gfap-Cre mice, in which IFNAR signaling was abrogat-
ed in glial fibrillary acidic protein–expressing (GFAP-expressing) 
astrocytes, to evaluate the contribution of astrocyte IFNAR signal-
ing to WNV pathogenesis and disease. For these studies, we chose 
the Gfap-Cre line 77.6, which was previously shown to exhibit a Cre 
expression that is more specific to astrocytes than to other Gfap-
Cre lines (22–25). We also used an established in vitro BBB model 
to examine how forebrain versus hindbrain astrocytes differential-
ly regulate barrier function. A deficiency in astrocyte IFNAR signal-
ing in mice with WNV encephalitis resulted in increased BBB per-
meability specifically within the hindbrain. WNV-infected Ifnarfl/fl 
Gfap-Cre+ mice exhibited decreased survival without increased 
viral replication or expanded tropism within hindbrain regions, but 
sustained immunopathologic neuronal death that could be miti-
gated via functional blockade of the leukocyte adhesion molecule 
VLA-4. Analysis of expression of PRRs and ISGs revealed higher 
baseline and IFN-induced levels in human and mouse cerebellar 
astrocytes compared with levels in cerebral cortical astrocytes. 
Our findings demonstrate an unrecognized function for astrocyte 
IFNAR signaling in the regulation of cerebellar BBB permeabil-
ity and indicate that astrocytes from evolutionarily distinct CNS 
regions show unique host defense programs.
Results
WNV infection in mice with global deletion of Ifnar leads to rapid 
death due to virus-induced sepsis (26). To assess the specific role 
of IFNAR signaling in astrocytes during WNV infection, we used 
8-week-old Ifnarfl/fl Gfap-Cre+ and Ifnarfl/fl Cre– littermate controls. 
Analysis of IFNAR expression in uninfected Ifnarfl/fl Gfap-Cre+ 
mice showed low expression of IFNAR in ALDH1L1+ astrocytes 
in both the cerebral cortex (12.5%) and cerebellum (10.7%) com-
pared with expression levels in controls (Supplemental Figure 1, 
A and B; supplemental material available online with this arti-
cle; https://doi.org/10.1172/JCI88720DS1). We did not observe 
substantial deletion of Ifnar in nonastrocytic cells, as IFNAR 
expression on ALDH1L1– cells remained intact compared with 
levels detected in controls in both cerebral cortex (95.7%) and 
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Figure 1. Survival and viral burden following s.c. WNV inoculation. (A–I) Mice were inoculated s.c. with WNV (New York 2000 strain). (A) Mice were 
monitored daily for survival after infection. (B) Clinical scores of Ifnarfl/fl mice either positive or negative for Gfap-Cre (x axis) were recorded on the indicated 
post-infection days. 0 = subclinical; 1 = hunched/ruffled fur; 2 = altered gate/slow movement; 3 = no movement, but responsive to stimuli; 4 = moribund; 
5 = dead. (C) Serum viral loads as measured by qRT-PCR. (D–G) Tissue viral loads as measured by plaque assay. (H) BBB permeability was measured by 
detection of sodium fluorescein accumulation in tissue homogenates derived from cerebral cortex or cerebellum. Data represent the mean ± SEM of 
individual mouse values normalized to serum sodium fluorescein concentration. Group means were then normalized to the mean values for uninfected 
controls. (I and J) Immunohistochemical detection of endogenous IgG accumulation in parenchymal CNS tissues. Signal intensities were quantified from 
two ×40 fields per region using ImageJ software. Scale bar: 100 μm. Data in A and B represent pooled data collected from 3 independent experiments for 
Ifnarfl/fl Cre– (n = 12), Ifnarfl/fl Gfap-Cre+ (n = 17), or Ifnar–/– (n = 8) mice. Data in C–G were collected from 2 to 3 independent experiments and represent values 
recorded for 4 to 10 mice per time point. Data in G–I were pooled from a total of 5 mice per time point and were collected from 2 independent experiments. 
*P < 0.05, **P < 0.01, and ***P < 0.001, by log-rank test (A), Mann-Whitney U test (C–G), or 2-way ANOVA (H and J).
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We questioned whether enhanced BBB permeability and 
WNV neuroinvasion in the cerebellum of Ifnarfl/fl Gfap-Cre+ mice 
were due to alterations in the regional expression of vasoactive 
cytokines, including type I IFNs, TNF-α, and IL-1β, as our previous 
studies showed that cytokine-mediated regulation of BBB perme-
ability can directly influence WNV movement across endotheli-
al barriers (4, 27, 28). On day 6 after s.c. inoculation with WNV, 
control Ifnarfl/fl Cre– cerebellar tissues showed higher levels of 
Ifnb (Figure 3A) and Ifna (Figure 3B) mRNA compared with cere-
bral cortex tissues with lower expression of the proinflammatory 
cytokine Il1b (Figure 3C). In contrast, Ifnarfl/fl Gfap-Cre+ cerebel-
lar tissues had higher levels of Il1b expression than did Ifnarfl/fl 
Cre– littermate controls, whereas expression of this cytokine in the 
cerebral cortex was unaffected by deletion of astrocytic Ifnar (Fig-
ure 3C). We observed no differences in Tnfa expression in either 
genotype at this time point (Figure 3D). By day 8 after infection, 
mRNA levels of type I IFNs, Il1b, and Tnfa were higher in tissues 
from both the cerebral cortex and cerebellum of Ifnarfl/fl Gfap-Cre+ 
mice, which likely reflected the higher viral titers found across the 
CNS at this time point (Figure 1, D–G). Differential cytokine gene 
expression in these tissues was confirmed at the protein level by 
ELISA (Supplemental Figure 6). These data suggest that enhanced 
cerebellar BBB permeability and WNV neuroinvasion in Ifnarfl/fl 
Gfap-Cre+ mice on day 6 (Figure 3, A and B) following s.c. infec-
tion are due in part to changes in the relative expression of barrier- 
stabilizing (e.g., type I IFNs) versus barrier-disrupting (e.g., IL-1β) 
cytokines (Figure 3, A and B versus Figure 3, C and D) (4).
During the course of these studies, we observed that expres-
sion of the inflammatory chemokines CCL2 and CXCL10, which 
are produced by WNV-infected neurons (31), was higher in cerebel-
points independently of enhanced neuroinvasion due to increased 
BBB permeability. To differentiate these hypotheses, we infected 
mice with WNV via an intracranial route, allowing us to bypass 
barriers to neuroinvasion and measure the kinetics of viral repli-
cation in CNS neurons directly. Viral titers did not differ between 
genotypes in cerebral cortical or cerebellar tissues following intra-
cranial inoculation with 10 PFU of WNV, regardless of whether 
virus was inoculated directly into the cerebral cortex (Figure 2A) 
or cerebellum (Figure 2B). Similar results were obtained follow-
ing intracerebellar inoculation with 10 PFU of WNV-Madagascar 
(Supplemental Figure 4), an attenuated strain that is more IFN 
sensitive than are highly pathogenic strains of WNV (30). Analo-
gous to tissue titers, BBB permeability did not differ significantly 
between genotypes following intracortical inoculation with WNV 
(Figure 2C), although cerebellar tissues showed a trend toward 
increased permeability. However, following intracerebellar inocu-
lation, BBB closure was diminished significantly in the cerebellum 
at early time points following infection of Ifnarfl/fl Gfap-Cre+ mice 
compared with Ifnarfl/fl Cre– littermate controls (Figure 2D), sug-
gesting that type I IFN signaling in astrocytes sustains BBB integri-
ty following detection of WNV by cerebellar tissues. Importantly, 
we observed no expansion of viral tropism to non-neuronal cells 
in Ifnarfl/fl Gfap-Cre+ mice following either s.c. (data not shown) or 
intracerebellar inoculation (Supplemental Figure 5), suggesting 
that disease burden in these mice is not driven by an aberrant sus-
ceptibility of astrocytes and other glia to infection. Together, these 
results suggest that higher viral titers in the cerebellum following 
s.c. infection in Ifnarfl/fl Gfap-Cre+ mice are due to defects in BBB 
restriction of neuroinvasion in the cerebellum during the early 
stages of CNS infection.
Figure 2. CNS replication and BBB permeability following intracranial inoculation. (A–D) Mice were inoculated with WNV (New York 2000 strain) via the 
intracranial route, and CNS tissues were harvested on the indicated post-infection days. (A and B) Cerebral cortex and cerebellar tissues were collected 
following intracranial inoculation within the cortex (A, intracortical inoculation) or cerebellum (B, intracerebellar inoculation). WNV titers were determined by 
standard plaque assay. (C and D) Cerebral cortex and cerebellar tissues were analyzed for accumulation of sodium fluorescein in tissue parenchyma following 
intracranial inoculation within the cortex (C, intracortical inoculation) or cerebellum (D, intracerebellar inoculation). Data represent the mean ± SEM of 
individual mouse values normalized to serum fluorescein concentration. Group means were then normalized to mean values for uninfected controls. Data 
in A–D were collected from 2 independent experiments and represent the mean values taken from a total of 5 mice per time point. Data were analyzed by 
Mann-Whitney U test (A and B) or 2-way ANOVA (C and D). **P < 0.01.
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deficiency of IFNAR signaling. To assess this, we examined sur-
vival following intracranial inoculation with WNV. Although all 
mice succumbed to infection in this model, intracranial infec-
tions allowed examination of the potential pathological impact 
of enhanced immune infiltration in the absence of differential 
viral titers. Remarkably, while intracortical inoculation with 
WNV resulted in no significant difference in overall survival 
rates between genotypes, Ifnarfl/fl Gfap-Cre+ mice had accelerated 
mortality compared with Ifnarfl/fl Cre– controls following intrace-
rebellar inoculation (Figure 4C). Immunohistochemical analysis 
revealed a broad parenchymal distribution of CD3+ lymphocytes 
(Figure 4D) and infiltrating IBA1+CD45hi myeloid cells (Supple-
mental Figure 7C) in the cerebella of infected Ifnarfl/fl Gfap-Cre+ 
mice on day 6 following intracerebellar inoculation. Infiltrating 
CD3+ T cells were associated with TUNEL+ apoptotic cells, espe-
cially in Ifnarfl/fl Gfap-Cre+ mice, which had higher numbers of 
apoptotic neurons and astrocytes compared with numbers detect-
ed in Ifnarfl/fl Cre– controls (Figure 4, E and F).
As type I IFN regulates immune trafficking by modulating 
VCAM-1 (CD106) expression on neurovascular cells (32–34), we 
determined whether the enhanced neuroinflammation in Ifnarfl/fl 
Gfap-Cre+ mice was associated with increased VCAM-1 expres-
sion. While VCAM-1 expression increased across the CNS follow-
ing WNV infection, Vcam-1 mRNA levels were further increased 
in the cerebellum but not in the cerebral cortex of Ifnarfl/fl Gfap-
Cre+ mice compared with Ifnarfl/fl Cre– controls on days 6 and 8 
after s.c. inoculation (Figure 5A and Supplemental Figure 8A). 
IFN-β treatment of either human or mouse primary astrocyte 
cultures from the cerebellum, but not from the cerebral cortex, 
significantly downregulated VCAM-1 expression (Figure 5B and 
Supplemental Figure 8B). Immunohistochemical analysis follow-
ing intracerebellar inoculation of Ifnarfl/fl Gfap-Cre+ mice revealed 
no genotype-dependent differences in VCAM-1 expression in the 
cerebral cortex (Figure 5C). In contrast, Ifnarfl/fl Gfap-Cre+ cer-
ebellar tissues showed enhanced VCAM-1 expression that was 
distributed across multiple cell types, including endothelial cells 
and astrocytes (Figure 5D). While VCAM-1 expression on vascular 
endothelium is a well-known regulator of neuroinflammation (35), 
VCAM-1 expression on astrocytes has also been shown to promote 
neuroinflammation by enhancing the penetration of infiltrating 
leukocytes out of perivascular spaces and into the CNS paren-
chyma (36, 37). Moreover, pharmacological blockade of VCAM-1 
binding to its ligand VLA-4 has previously been shown to decrease 
pathogenic neuroinflammation and improve survival following 
s.c. WNV infection (38). Given that IFNAR signaling in astrocytes 
downregulated VCAM-1 expression in the cerebellum following 
WNV infection, we questioned whether VCAM-1 expression con-
tributed to the enhanced immune infiltration and immunopathol-
lar tissues following infection, with Ifnarfl/fl Gfap-Cre+ mice show-
ing even higher levels of Ccl2 and Cxcl10 expression in cerebellar 
tissues (Figure 3, E and F) than were detected in their littermate 
Ifnarfl/fl Cre– controls. Because of this result, we evaluated whether 
the increased expression of leukocyte chemoattractant molecules 
in Ifnarfl/fl Gfap-Cre+ mice resulted in differences in CNS immune 
cell infiltration. Although the total number of infiltrating immune 
cells in the cerebral cortex was unchanged in Ifnarfl/fl Gfap-Cre+ 
mice compared with the total number in Ifnarfl/fl Cre– controls on 
day 8 following s.c. inoculation with WNV (Supplemental Figure 
7A), there were greater numbers of CD8+ IFN-γ+ lymphocytes and 
CD45hiCD11bloF4/80+ macrophages in the cerebellum (Supple-
mental Figure 7B). As enhanced inflammatory infiltrates may be a 
secondary consequence of higher viral titers in Ifnarfl/fl Gfap-Cre+ 
mice following s.c. infection, we performed a similar analysis of 
CNS immune infiltrates on day 6 following intracerebellar inocu-
lation with WNV, as viral titers are indistinguishable between gen-
otypes in this model. These experiments showed no significant 
differences in immune cell infiltration between genotypes in the 
cerebral cortex, but again revealed greater infiltration of several 
leukocyte subsets (e.g., T lymphocytes and macrophages) in the 
cerebellum of Ifnarfl/fl Gfap-Cre+ mice compared with Ifnarfl/fl Cre– 
littermate controls (Figure 4, A and B). These data suggest that, 
even in the presence of similar viral titers, type I IFN signaling in 
cerebellar astrocytes suppresses neuroinflammation.
We questioned whether the increased immune infiltration in 
the cerebellum of Ifnarfl/fl Gfap-Cre+ mice was a pathologic rath-
er than protective response in the setting of astrocyte-specific 
Figure 3. Cytokine and chemokine expression in the CNS following s.c. 
inoculation. (A–F) Mice were s.c. inoculated with WNV. Cerebral cortex 
and cerebellar tissues were extracted on the indicated post-infection days. 
Relative transcript levels in tissue homogenates were measured by SYBR 
qRT-PCR for the indicated cytokines and chemokines. Data for individual 
mice were normalized to Gapdh. Data represent the mean ± SEM from a 
total of 5 to 6 mice and were collected from 2 independent experiments. 
All data were analyzed by 2-way ANOVA. *P < 0.05 and ***P < 0.001.
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Figure 4. CNS immune cell trafficking and immunopathology following intracranial inoculation. (A and B) Flow cytometric analysis of CNS immune cell 
infiltrates on day 6 following intracerebellar infection. (A) Representative flow cytometric dot plots demonstrating the percentages of CD45hi versus CD45lo 
brain leukocytes isolated from the cerebral cortex and cerebellum of mock- and WNV-infected mice. The representative panel for mock infection is for an 
Ifnarfl/fl mouse, which resembles mock infection in Gfap-Cre+ mice (shown here). The numbers indicate the percentage of each cell type within the total 
number of cells isolated (after exclusion of doublets and dead cell debris). (B) Total number of CD45+ leukocytes, CD45hiCD4+ and CD45hiCD8+ lymphocytes 
expressing IFN-γ, and CD45loCD11b+F4/80+ microglia and CD45hiCD11b+F4/80+ macrophages isolated from the indicated brain region. Data in B were collected 
from 2 independent experiments and represent the mean ± SEM for 6 mice. Note that data in A and B were not normalized for the greater tissue volume 
of the cerebral cortex versus the cerebellum. (C) Survival was monitored following either intracortical or intracerebellar inoculation. Survival data for 10 to 
11 mice per group were pooled from 2 independent infections. (D and E) Immunohistochemical detection of TUNEL+ nuclei of dead and dying cells in the 
cerebellar granule cell layer, costained for CD3+ T lymphocytes (D), NeuN+ neurons (E), or S100-β+ astrocytes (E). Scale bars: 50 μm. (F) Quantification of dead 
and dying neurons (TUNEL+NeuN+) or astrocytes (TUNEL+S100-β+), generated by counting cells that were double positive for TUNEL and the appropriate cell 
marker (depicted in pixel-masked images to the right of the merged RGB images in E). Data were determined by counting 4 images from 2 nonserial sections 
per mouse (n = 5 mice/group). Counts for each image were normalized to the total area of the granule cell layer present per high-power field. Graphed data 
points represent averages for all images taken for individual mice. All data represent pooled values from 2 independent experiments and were compared 
using an unpaired, 2-tailed Student’s t test (B and F) or log-rank test (C). *P < 0.05  and **P < 0.01. All error bars are SEM. 
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ogy observed in Ifnarfl/fl Gfap-Cre+ mice. Thus, we tested whether 
blockade of VCAM-1–VLA-4 binding would protect Ifnarfl/fl Gfap-
Cre+ mice following WNV infection. Daily administration of a 
small-molecule antagonist of VLA-4 (BIO5192) starting on day 
4 following intracerebellar infection extended survival in Ifnarfl/fl 
Gfap-Cre+ mice, without impacting survival in the Ifnarfl/fl Cre– lit-
termate controls (Figure 6A). Flow cytometric analysis on day 6 
after infection revealed that BIO5192 treatment modestly reduced 
the number of infiltrating lymphocytes and macrophages in Ifnarfl/fl 
Cre– littermates, with only differences in macrophage numbers 
reaching statistical significance (Figure 6B). In contrast, VLA-4 
blockade significantly reduced infiltrating lymphocyte and mac-
rophage numbers in Ifnarfl/fl Gfap-Cre+ cerebella to levels indis-
tinguishable from those detected in littermate controls. BIO5192 
treatment also reduced the numbers of TUNEL+ neurons and 
astrocytes (Figure 6, C and D) in the cerebella of Ifnarfl/fl Gfap-Cre+ 
Figure 5. VCAM-1 expression in cerebellar 
astrocytes in vitro and in the CNS in vivo 
following infection. (A and B) Vcam-1 mRNA 
levels were detected by SYBR qRT-PCR. (A) 
Vcam-1 mRNA levels were detected in the 
cerebella of mice taken on the indicated days 
following s.c. infection. (B) VCAM-1 mRNA 
levels in primary adult human cerebellar 
astrocytes and primary murine neonatal 
cerebellar astrocytes following a 4-hour 
treatment with 10 U/ml IFN-β. Ct values in 
A and B were normalized to the Ct values 
of the housekeeping gene Gapdh. (C and D) 
Immunohistochemical detection of VCAM-1 
expression on CD31/endomucin+ (cocktail+) 
endothelial cells and S100-β+ astrocytes in 
the cerebral cortex (C) or cerebellum (D). 
Scale bars: 50 μm. VCAM-1 expression on 
the indicated cell type was quantified as the 
mean VCAM-1 (green) fluorescence inten-
sity of pixels that stained positive for the 
indicated cell marker. Data were obtained 
after quantifying 4 images from 2 randomly 
chosen, nonserial sections per mouse (81,000 
μm2 total analyzed area per mouse, 5 mice 
per group). Data are reported as log10 arbitrary 
fluorescence intensity units. Data in A–D are 
from 2 independent experiments and are 
representative images or the mean ± SEM of 
5 to 6 replicates per mouse per group.  
***P < 0.001, by 2-way ANOVA.
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ferentially impacts BBB function. We generated in vitro BBB cul-
tures in which primary murine BMECs derived from the cerebral 
cortex were cocultured on inserts above astrocytes derived from 
the cerebellum or cerebral cortex. Measurements of BBB integri-
ty were taken by recording transendothelial electrical resistance 
(TEER), as described previously (4). While in vitro BBB cultures 
with cerebral cortex or cerebellar astrocytes did not exhibit base-
line differences in TEER, the addition of IFN-β to the bottom 
chamber resulted in an enhancement of TEER in cultures with 
mice on day 6 after infection. Thus, blockade of VCAM-1 in Ifnarfl/fl 
Gfap-Cre+ mice following WNV infection decreased inflamma-
tion and immunopathology specifically in the cerebellum. These 
data indicate that enhanced expression of leukocyte migratory 
cues and the resultant neuroinflammation contribute directly to 
the enhanced CNS tissue injury and animal mortality observed in 
Ifnarfl/fl Gfap-Cre+ mice following intracranial WNV infection.
In light of these findings, we next assessed whether IFN sig-
naling in astrocytes from the cerebellum and cerebral cortex dif-
Figure 6. Survival, immune infiltrates, and immunopathology following pharmacological blockade of VLA-4. (A–D) Mice were inoculated via an intrace-
rebellar route with WNV. Infected mice in all experiments were treated i.p. with 10 mg/kg BIO5192, a small-molecule VLA-4 antagonist, or vehicle solution 
beginning on day 4 after infection. (A) Survival was monitored daily following infection (n = 7 mice/group). (B) Flow cytometric analysis of immune 
infiltrates in the cerebellum on day 6 after infection (n = 4 mice/group) (C) Immunohistochemical detection of TUNEL+ neurons (NeuN, left) and astrocytes 
(S100-β, right) in cerebellar granule cell layers of infected mice on day 6 after infection. Scale bar: 50 μm. (D) Quantification of dead and dying neurons (left 
panel) or astrocytes (right panel), generated by counting cells double positive for TUNEL and the appropriate cell marker (depicted in pixel masked images 
to the right of merged RGB images). Data are taken from counting 4 images from 2 nonserial sections per mouse (5 mice/group). Counts for each image 
were normalized to the total area of granule cell layer present per high-power field. All data represent pooled values from 2 independent experiments.  
*P < 0.05 , **P < 0.01, and ***P < 0.001, by log-rank test (A) or 2-way ANOVA (B and D).
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gene expression between astrocytes from cerebral cortex and 
those from cerebellum across both treatment conditions (Figure 
7I). Pathway analysis of these genes revealed that many relevant 
pathways were differentially regulated in astrocytes from either 
region, including IFN signaling and IRF activation of cytosolic 
PRRs (Supplemental Table 1). Of note, other potentially important 
pathways that exhibited differential regulation included innate 
immune pathways such as death receptor signaling and retinoic 
acid–mediated apoptosis; moreover, pathways relevant to BBB 
biology, including TJ signaling and adherens junction signaling, 
were also differentially regulated across regions. Further analysis 
confirmed our previous finding that homeostatic and IFN-induced 
expression of ISGs and PRRs was higher in cerebellar astrocytes 
than in astrocytes from cerebral cortex (Supplemental Tables 2 
and 3). Examples of IFN-related genes expressed more highly in 
cerebellar astrocytes include Ifit1, Ifit2, Ifit3, IFN-induced with 
helicase C domain 1 (Ifih1, also known as MDA5), IFN-γ–induc-
ible protein 16 (Ifi16), IFN-induced protein 44 like (Ifi44l), MX 
dynamin-like GTPase 1 (Mx1), radical S-adenosyl methionine 
domain–containing 2 (Rsad2, also known as viperin), and Stat1. 
While not every gene identified in our quantitative reverse tran-
scription PCR (qRT-PCR) studies met the threshold for statistical 
significance in our RNA-seq analysis, these studies confirm broad 
differential regulation of innate immune and IFN signaling path-
ways in astrocytes isolated from cerebellum compared with those 
from cerebral cortex.
Discussion
Alterations in BBB biology and function during neurotropic viral 
infection have been presumed to arise from uniform responses of 
BMECs throughout the CNS vasculature. In this study, we demon-
strate that innate immune responses of astrocytes from evolu-
tionarily distinct regions of the CNS contribute to BBB heteroge-
neity via differential activation of antiviral signaling pathways. 
Our studies indicate differential roles for type I IFN signaling in 
hindbrain and forebrain astrocytes, as loss of IFNAR signaling in 
astrocytes resulted in enhanced BBB permeability, early viral neu-
roinvasion, and increased immunopathologic neuronal cell death 
in the cerebellum of mice following WNV infection. Studies using 
both human and mouse astrocytes showed enhanced basal and 
IFN-induced expression of PRRs and ISGs in cerebellar astrocytes 
compared with expression levels in cortical astrocytes, suggesting 
that cerebellar astrocytes are primed for more rapid IFN respons-
es upon detection of CNS pathogens, leading to greater enhance-
ment of BBB function and suppression of neuroinflammation.
These findings increase our understanding of the immuno-
logic heterogeneity of the CNS. A growing body of research has 
established the differential susceptibility of CNS regions to infec-
tion and autoimmunity (15, 18, 31, 39), though the resident CNS 
cells and signaling pathways that underlie these heterogeneities 
remain poorly understood. As an example, neurons of hindbrain 
and forebrain regions exhibit differential type I IFN signaling in 
response to positive-strand RNA viruses (18), and, in general, type 
I IFN responses to viruses vary among neuronal subtypes and their 
stages of differentiation (18, 40–42). While nonspecific neuronal 
deletion of Ifnar in our study could confound analyses of similar 
regional phenotypes in astrocytes, the Gfap-Cre line 77.6 has been 
cerebellar astrocytes, beyond that observed in cultures with astro-
cytes from the cerebral cortex (Figure 7A).
To assess whether astrocytes derived from different brain 
regions could influence the ability of WNV to cross an intact BBB, 
we generated in vitro BBB cultures composed of uniform cultures 
of WT BMECS grown on inserts above either WT or Ifnar–/– astro-
cytes derived from either the cerebral cortex or cerebellum. WNV 
was placed into the top chamber of the cultures for 6 hours, after 
which viral trafficking was measured by extracting and combining 
RNA from the supernatants and astrocytes of the bottom cham-
bers. We observed less viral trafficking to the bottom chambers 
of the cultures with WT cerebellar astrocytes than to those with 
WT cerebral cortical astrocytes (Figure 7B). However, we did not 
observe this difference when astrocytes were deficient in IFNAR. 
Pretreatment of cultures with IFN-β effectively limited viral traf-
ficking across in vitro BBB in all cultures, consistent with our pre-
vious report showing synergistic effects of IFN signaling in endo-
thelial cells and astrocytes on the modulation of WNV trafficking 
in vitro (4). However, IFN-β treatment suppressed viral trafficking 
more robustly in cultures with WT cerebellar astrocytes than in 
those with cerebral cortex astrocytes, and this difference was lost 
when astrocytes lacked IFNAR expression (Figure 7B), suggesting 
that cerebellar astrocytes are better able than are cerebral cortical 
astrocytes to positively regulate BBB function following stimula-
tion with type I IFN.
Given the differences in the efficacy of IFN signaling in astro-
cytes derived from different brain regions, we explored whether 
IFN signaling programs in astrocytes from these regions were dif-
ferent. We compared transcript levels of canonical ISGs between 
human astrocytes derived from the cerebral cortex and cerebel-
lum. Remarkably, we observed enhanced basal expression of 
several ISGs, including the PRR TLR7, the transcription factor 
IFN regulatory factor 3 (IRF3), and other major antiviral or proin-
flammatory genes (IFN-induced protein with tetratricopeptide 
repeats 1 [IFIT1], 2′-5′-oligoadenylate synthetase 1 [OAS1], and 
C-X-C motif chemokine ligand 11 [CXCL11]) (Figure 7, C–H). In 
contrast, basal expression of other PRR and signaling molecules 
(e.g., TLR3 and IRF7) did not differ between the 2 types of astro-
cytes (data not shown). Moreover, astrocytes derived from the 
cerebellum exhibited enhanced expression of ISGs after 4 hours 
of treatment with IFN-β, though by 24 hours, both astrocyte pop-
ulations reached expression levels equivalent to those of most 
ISGs. These data suggest that astrocytes from the cerebellum are 
primed at baseline with enhanced type I IFN signatures compared 
with astrocytes from the cerebral cortex and reach maximal ISG 
expression more rapidly following IFN stimulation. This pattern 
was not unique to human astrocytes. While baseline expression of 
the type I and type III IFN receptors IFNAR1 and IFNLR1 did not 
differ, we observed higher basal and IFN-induced expression of 
ISG mRNAs and proteins in primary murine cerebellar astrocytes 
compared with expression levels in those from the cerebral cortex 
(Supplemental Figure 9, A–I).
To generate a more complete picture of differential gene 
expression, we next performed mRNA sequencing (RNA-seq) 
in primary human astrocytes from either brain region follow-
ing 4 hours of treatment with IFN-β or a PBS vehicle. Our anal-
ysis of global gene expression revealed substantial differential 
Downloaded from http://www.jci.org on April 17, 2017.   https://doi.org/10.1172/JCI88720
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
8 5 2 jci.org   Volume 127   Number 3   March 2017
Figure 7. Type I IFN responses in astrocytes in vitro. (A and B) In vitro BBB Transwell cultures were generated with either cerebral cortical or cerebellar 
astrocytes. (A) TEER recordings in cultures treated with saline vehicle or 10 U/ml recombinant IFN-β. (B) Cultures were generated with cerebral cortical or 
cerebellar astrocytes (x axis) derived from either WT (black bars) or Ifnar–/– mice (orange bars) and treated overnight with either saline vehicle or 10 U/ml 
recombinant IFN-β. Following pretreatment, WNV (0.01 MOI) was added to the top chamber of cultures and allowed to migrate for 6 hours. Data represent 
combined WNV genome copy numbers detected in the astrocyte monolayer and bottom chamber supernatant. (C–H) Primary human cerebral cortical 
or cerebellar astrocytes were treated with 10 U/ml recombinant IFN-β and analyzed for transcript expression of the indicated genes 4 and 24 hours after 
treatment. Ct values for all genes were normalized to Ct values of the housekeeping gene GAPDH. (I) Primary human cerebral cortical or cerebellar astro-
cytes were treated for 4 hours with PBS or 10U/ml recombinant IFN-β and subjected to RNA-seq. Heatmap and histogram of global gene expression across 
regions and treatment groups were generated from all statistically significant genes. Data in A–H represent the mean ± SEM of 5 to 6 replicates from 2 
to 3 independent experiments and were analyzed by 2-way ANOVA. Data in I were derived from 3 independent samples per group and were analyzed as 
described in the Methods. *P < 0.05 , **P < 0.01, and ***P < 0.001. Cbl, cerebellum; Ctx, cortex.
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hindbrain tissues. This role is supported by studies demonstrating 
that pharmacological blockade of VLA-4 in the context of neuro-
tropic viral infection can ameliorate disease, largely via suppres-
sion of CNS immunopathology (38, 53). We note, however, that 
the experimental consequences of VLA-4 blockade are likely con-
text dependent, varying by disease model and timing of treatment 
after infection, and that this blockade may act through additional 
VLA-4 ligands beyond VCAM-1, including JAM-B and fibronectin 
(56). Moreover, modulation of VCAM-1 is likely only one of sever-
al relevant regulatory outputs of type I IFN signaling in astrocytes 
and probably acts in concert with independent effects on inflam-
matory cytokine expression and BBB function to coordinate neu-
roinflammation during WNV infection.
Our study demonstrating a role for astrocytes in limiting 
inflammation via the regulation of BBB permeability has clinical 
implications. Loss of BBB integrity in the hindbrain, as evidenced 
by gadolinium contrast–enhanced magnetic resonance imaging 
(Gd-MRI), is associated with poor prognosis in patients with WNV 
neuroinvasive disease (19, 57). As Gd-MRI–enhanced lesions 
develop in conjunction with inflammatory infiltrates, alteration in 
vascular permeability is believed to occur in tandem with the cap-
ture and trafficking of leukocytes from the blood at endothelial bar-
riers (58, 59). Indeed, recent studies indicate that increased BBB 
permeability predicts the development of neuroinflammation in 
patients with CNS autoimmunity (60). Although impaired VLA-4 
function is known to jeopardize host protection during acute viral 
infection of the CNS (61), our study suggests that patients with 
acute WNV encephalitis and persistent cerebellar inflammation 
and disease symptoms might benefit from VLA-4 blockade. In 
summary, these findings advance our understanding of astrocyte 
innate immune responses during viral infection, identify region-
ally distinct roles for astrocytes in the regulation of BBB function, 
and suggest that defining signaling pathways that modulate leuko-
cyte entry into distinct brain regions can identify new targets for 
the prevention and treatment of CNS immunopathology.
Methods
Mouse models of WNV encephalitis. All animals used in this study were 
infected at 8 weeks of age. The Gfap-Cre+ line 77.6 was obtained com-
mercially from The Jackson Laboratory and maintained in the hemizy-
gous state. Ifnarfl/fl mice were obtained from R. Schreiber (Washington 
University School of Medicine, St. Louis, Missouri, USA) and U. Kalin-
ke (Paul-Ehrlich-Institut, Hannover, Germany). Ifnarfl/fl mice (62) 
were backcrossed using speed congenic analysis to 99% C57BL/6J 
as judged by microsatellite analysis. All animals were housed under 
specific pathogen–free conditions. Littermates for the survival stud-
ies performed and depicted in Figure 1A were derived from crosses of 
Ifnarfl/WT Gfap-Cre+ with Ifnarfl/fl breeders. Subsequently, littermates 
were obtained from breeders on a homozygous Ifnarfl/fl background 
(Ifnarfl/fl Gfap-Cre+/– with Ifnarfl/fl). Inoculation via footpad s.c. injec-
tion (50 μl) or intracranial inoculation (10 μl) was performed with 
either 102 or 10 PFU of WNV, respectively, as previously described 
(63). WNV (strain 3000.0259, isolated in New York in 2000) (64) was 
used in all experiments except those depicted in Supplemental Figure 
5, in which the WNV-Madagascar (strain DakAnMg798, isolated in 
1978) (65) also was used. Viral titers in all studies were assessed via 
plaque assay in BHK21-15 cells, as previously described (66).
shown in numerous studies to have reliably astrocyte-specific 
expression (22–25). Consistent with this, we observed deletion 
of Ifnar on cortical and cerebellar astrocytes, with intact expres-
sion of the receptor on nonastrocytic cells. The lack of alterations 
in virologic and immunologic parameters in the periphery or 
after intracortical inoculation of virus also suggests that there is 
little nonspecific deletion of Ifnar in neurons or peripheral cells. 
Although regional heterogeneity in astrocyte neurophysiolog-
ic functions has been appreciated (15, 43, 44), few studies have 
evaluated the differential responses of these astrocytes to viral 
infections. Our study suggests that differential IFN signaling in 
hindbrain regions is multicellular in nature and may be common 
to all cells of neuroectodermal lineage in the hindbrain. The con-
firmation of these findings in neurons and astrocytes from both 
murine and human sources suggests a phenomenon that may be 
conserved in recent evolution and that perhaps serves to protect 
centers of vital autonomic function in the cerebellum and brain-
stem from pathogenic and immunologic injury.
Our findings highlight the multifaceted contributions of astro-
glia to the regulation of CNS immune responses. Loss of IFNAR 
signaling in astrocytes has multiple consequences, including the 
enhanced expression of inflammatory cytokines and chemokines, 
which can disrupt the BBB during neurotropic viral infection (4, 6, 
7). This enhanced BBB permeability is associated with earlier detec-
tion of WNV in hindbrain regions of the CNS, suggesting that astro-
cyte IFNAR signaling prevents or delays infection at this site. Altered 
expression of cytokines such as IL-1β also probably influences other 
functions of the BBB, including local antigen presentation (21, 45) 
and perivascular capture of infiltrating leukocytes (9, 46), as reflect-
ed by the broad parenchymal localization of CD3+ lymphocytes in 
our study. Regional differences in astrocyte signaling may also dif-
ferentially impact regional differences in other neurovascular cell 
types, including endothelial cells. While WNV may enter the CNS 
via multiple mechanisms, including nonhematogenous routes such 
as retrograde axonal transport (47) and transynaptic trafficking (48), 
the critical role of BBB function in limiting WNV neuroinvasion and 
subsequent disease burden has been established in many recent 
studies (4, 27, 28). Moreover, sciatic nerve ligation ipsilateral to the 
footpad used for s.c. inoculation does not rescue CNS infection or 
mortality in mice (47), suggesting that hematogenous spread alone 
is sufficient for severe neuroinvasive infection. Thus, the alterations 
to BBB function observed in our study probably contributed signifi-
cantly to the enhanced disease pathogenesis we observed in Ifnarfl/fl 
Gfap-Cre+ mice following WNV infection.
IFNAR signaling in astrocytes was important for the suppres-
sion of VCAM-1 expression in neurovascular cells of the hindbrain. 
A potential mechanism for this effect is type I IFN–mediated sup-
pression of inflammatory cytokines. For example, several recent 
studies have described a role for type I IFN in suppressing the 
expression of IL-1β (4, 49, 50), which is known to induce VCAM-1 
expression in astrocytes (51, 52). VCAM-1–VLA-4 interactions 
facilitate immune trafficking during CNS infection (38, 53). 
Although CNS immune infiltration is required for viral clearance 
following WNV infection (9, 54), high levels of inflammatory cell 
infiltration are associated with pathology and bystander injury (11, 
45, 55). Thus, astrocyte IFNAR–mediated suppression of VCAM-1 
expression appears to play a protective antiinflammatory role in 
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naling Technology; 93700P). Membranes were washed 3 times with 
water, followed by a 3-hour incubation at room temperature with 
anti-mouse DyLight 800 (Thermo Fisher Scientific; 52575) and goat 
anti-rabbit IRDye 680RD (LI-COR; 925-68071) secondary antibod-
ies. Membranes were washed 3 times with TBS Tween-20 (TBST) and 
imaged using the Odyssey Gel Imaging System (LI-COR).
Astrocyte and in vitro BBB cultures. Primary cerebral cortex and 
cerebellar human astrocytes were obtained from ScienCell Research 
Laboratories (catalogs 1800 and 1810) and grown according to the 
manufacturer’s protocols in ScienCell Astrocyte Medium (catalog 
1801). Primary neonatal mouse astrocytes were obtained and main-
tained as previously described (4). Immunohistochemical character-
ization of primary human and murine astrocytes using anti–S100-β 
(Abcam; ab41548) and anti-ALDH1A1 (Abcam; ab52492) antibodies 
in conjunction with nuclear stains (TO-PRO-3) revealed a greater than 
99% purity. In vitro BBB cultures were generated with primary mouse 
BMECs and astrocytes and used in TEER and viral migration assays as 
previously described (4, 27).
IFN treatment. Astrocyte and in vitro BBB cultures were treated in 
normal culture medium with 10 U/ml mouse or human recombinant 
IFN-β (PBL Assay Sciences) or 0.1% BSA in PBS vehicle, as appropri-
ate. Cytokines were added to the bottom chamber of in vitro BBB cul-
tures. Endothelial cells and astrocytes remained in coculture for the 
duration of the cytokine treatment.
VLA-4 blockade studies. The VLA-4 antagonist BIO5192 (Tocris 
Bioscience) was reconstituted in aqueous vehicle containing ethanol 
and propylene glycol as described previously (56). A daily dosage of 10 
mg/kg was chosen on the basis of published studies of serum half-life 
and receptor occupancy (56, 68). All injections were given i.p. begin-
ning on day 4 after WNV infection.
RNA-seq. Human astrocytes from cerebral cortex or cerebellum 
were cultured and treated for 4 hours with PBS or recombinant IFN-β 
as described above. Total RNA was extracted using an RNeasy Kit 
(QIAGEN) and prepared for sequencing. Raw RNA-seq data (FASTQ 
files) were demultiplexed and checked for quality (FASTQC), and 
adapters and rRNA were digitally removed (cutadapt, version 1.8.3 and 
Bowtie2, version 2.2.5). Sufficient reads were generated (~30 million 
reads) and then mapped to the human genome (NCBI build 37.1). Raw 
reads were aligned to the host genome using STAR (2.4.2) and then 
converted into gene counts with HTSeq (version 0.6.0). Gene counts 
were filtered by a mean of 10 or greater across all samples. Explorato-
ry analysis and statistics were run using the R statistical programming 
language (version 3.2.0). The gene count matrix was normalized using 
voom through the Bioconductor limma package (version 3.26.9). Sta-
tistical analysis (including differential expression) was performed 
using R and Bioconductor. Sequencing data were deposited in the 
NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE89476).
Statistics. Survival experiments were analyzed by log-rank test. 
Viral titers in tissue were analyzed by Mann-Whitney U test. Other 
experiments were analyzed with parametric tests (2-tailed Student’s t 
test or 2-way ANOVA), with correction for multiple comparisons where 
appropriate. All statistical analysis except for RNA-seq analysis was per-
formed using GraphPad Prism Version 7 software (GraphPad Software). 
A P value of less than 0.05 was considered statistically significant.
Study approval. All experiments were performed in compliance 
with and under the approval of the Washington University Animal 
Studies Committee.
Immunohistochemical analysis. CNS tissue sections were 
obtained after cardiac perfusion with 4% paraformaldehyde in PBS. 
Tissues were frozen, blocked, and stained as previously described 
(31) with primary antibodies against IFNAR1 (BioLegend; 127305); 
S100-β (Abcam; ab41548); CD31/endomucin antibody cocktail 
(BD, 550274 and eBioscience, 14-5851-81) (67); VCAM-1 (Abcam; 
ab134047); ALDH1L1 (Abcam; ab52492); NeuN (EMD Millipore; 
MAB277B); and CD3 (Abcam; ab16044). Secondary fluorescence 
staining was performed with the appropriate Alexa Fluor 488 and 
555 antibodies (Life Technologies, Thermo Fisher Scientific). Nuclei 
in all preparations were stained with TO-PRO-3 (Life Technologies, 
Thermo Fisher Scientific). TUNEL staining was performed with a 
TMR Red In Situ Cell Death Detection Kit (Roche). All images were 
acquired via confocal microscopy (Carl Zeiss). Image analysis was 
performed with ImageJ software (NIH). Details on individual analy-
ses are provided in the figure legends.
In vivo assessment of BBB permeability. Sodium fluorescein per-
meability experiments were performed as previously described (4). 
Briefly, on predetermined days following infection, mice were inject-
ed i.p. with 100 μl of 100 mg/ml fluorescein sodium salt (Sigma- 
Aldrich) in sterile PBS. Tissue homogenates and serum were collect-
ed following perfusion with PBS and then incubated overnight in 2% 
TCA (Sigma-Aldrich) to precipitate protein. Supernatants were dilut-
ed in equal volumes of borate buffer, pH 11.0 (Sigma-Aldrich). Tissue 
fluorescence values were determined with a fluorometric plate reader 
and standardized against plasma fluorescence values for individual 
mice. Fluorescence staining for extravasated endogenous IgG was 
performed as previously described (27).
CNS leukocyte isolation and flow cytometric analysis. Leukocytes 
were isolated from freshly dissected CNS regions following PBS per-
fusion and stained with fluorescently conjugated antibodies to CD3, 
CD4, CD8β, CD11b, F4/80, and CD45 as previously described (21). 
Intracellular IFN-γ staining was performed on isolated leukocytes in 
an I-Ab–restricted NS3-2066 and NS3-1616 peptide and a Db-restrict-
ed NS4B peptide restimulation assay as previously described (27). An 
LSR Flow Cytometer (BD) and FlowJo software (Tree Star) were used 
for data acquisition and analysis.
qRT-PCR analysis. Total RNA was collected from freshly dissect-
ed CNS regions following PBS perfusion or from cell cultures using an 
RNeasy Kit (QIAGEN) according to the manufacturer’s instructions. 
Reverse transcription and SYBR Green qRT-PCR were performed for 
cytokine, chemokine, and ISG analytes as previously described (31). Ct 
values for all genes were normalized to Ct values of the housekeeping 
gene GAPDH. Data from qRT-PCR experiments are reported as ΔCt 
(Cttarget – CtGAPDH). Primers used for all analyses are reported in Supple-
mental Table 4. qRT-PCR analysis of WNV copy numbers in serum and 
cell culture supernatants was performed with TaqMan reagents (Thermo 
Fisher Scientific) as previously described (27, 66).
Western blotting. Protein lysates were collected in radioimmuno-
precipitation assay (RIPA) buffer (Sigma-Aldrich), separated on NuP-
age 4%–12% Bis-Tris Gels (Invitrogen, Thermo Fisher Scientific), and 
transferred to nitrocellulose membranes via the iBlot 2 transfer system 
(Thermo Fisher Scientific). Membranes were incubated overnight at 
4ºC in TBS plus 4% powdered milk with the following primary anti-
bodies: anti-IFIT1 mAb (13B4-1, unpublished antibody developed in 
the laboratory of Michael Diamond); anti-IFIT2 polyclonal antibody 
(Thermo Fisher Scientific; PA3-845); and anti–β actin mAb (Cell Sig-
Downloaded from http://www.jci.org on April 17, 2017.   https://doi.org/10.1172/JCI88720
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
8 5 5jci.org   Volume 127   Number 3   March 2017
supported by a National Science Foundation Graduate Research 
Fellowship (DGE-1143954) and an NIH NRSA fellowship (F31-
NS07866). JLW was supported by a postdoctoral fellowship from 
the National Multiple Sclerosis Society. JPW was supported by an 
NIH NRSA fellowship (F32-AI112274). Experimental support was 
provided by the Speed Congenics Facility of the Rheumatic Dis-
eases Core Center (Washington University School of Medicine, St. 
Louis, MO, USA). Research reported in this article was supported 
by the National Institute of Arthritis and Musculoskeletal and Skin 
Diseases, part of the NIH, under award number P30AR048335. 
The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the NIH.
Address correspondence to: Robyn S. Klein, 660 S. Euclid Avenue, 
St. Louis, Missouri 63110, USA. Phone: 314.286.2140; E-mail: 
rklein@wustl.edu.
Author contributions
Conceptualization: BPD and RSK; methodology: BPD, MSD, and 
RSK; analysis: BPD, HJ, DMD, JLW, RRG, and HML; investigation: 
BPD, HJ, DMD, JLW, JPW, and HML; writing of the original draft: 
BPD and RSK; review and editing of the manuscript: BPD, JLW, 
HML, MSD, and RSK; supervision and funding acquisition: MG, 
MSD, and RSK.
Acknowledgments
We thank Denise Dorsey, Qingping Wu, and Matthew Cain for their 
technical assistance (Washington University School of Medicine, 
St. Louis, MO, USA). We also thank the University of Washington’s 
Center for Innate Immunity and Immune Disease Immuno-Infor-
matics core group for their bioinformatics support. This work was 
supported by NIH grants U19 AI083019 (to RSK, MSD, and MG), 
R01 NS052632 (to RSK), and R01 AI104002 (to MG). BPD was 
 1. Platanias LC. Mechanisms of type-I- and 
type-II-interferon-mediated signalling. Nat Rev 
Immunol. 2005;5(5):375–386.
 2. Lazear HM, Diamond MS. New insights into 
innate immune restriction of West Nile virus 
infection. Curr Opin Virol. 2015;11:1–6.
 3. Schoggins JW, Rice CM. Interferon-stimulated 
genes and their antiviral effector functions. Curr 
Opin Virol. 2011;1(6):519–525.
 4. Daniels BP, Holman DW, Cruz-Orengo L, 
Jujjavarapu H, Durrant DM, Klein RS. Viral 
pathogen-associated molecular patterns regulate 
blood-brain barrier integrity via competing innate 
cytokine signals. MBio. 2014;5(5):e01476–e01414.
 5. Persidsky Y, Ramirez SH, Haorah J, Kanmogne 
GD. Blood-brain barrier: structural components 
and function under physiologic and patho-
logic conditions. J Neuroimmune Pharmacol. 
2006;1(3):223–236.
 6. Daniels BP, Klein RS. Viral sensing at the blood-
brain barrier: new roles for innate immunity 
at the CNS vasculature. Clin Pharmacol Ther. 
2015;97(4):372–379.
 7. Pan W, Stone KP, Hsuchou H, Manda VK, Zhang 
Y, Kastin AJ. Cytokine signaling modulates 
blood-brain barrier function. Curr Pharm Des. 
2011;17(33):3729–3740.
 8. Chai Q, He WQ, Zhou M, Lu H, Fu ZF. Enhance-
ment of blood-brain barrier permeability and 
reduction of tight junction protein expression 
are modulated by chemokines/cytokines 
induced by rabies virus infection. J Virol. 
2014;88(9):4698–4710.
 9. McCandless EE, Zhang B, Diamond MS, Klein 
RS. CXCR4 antagonism increases T cell traffick-
ing in the central nervous system and improves 
survival from West Nile virus encephalitis. Proc 
Natl Acad Sci USA. 2008;105(32):11270–11275.
 10. Zhao L, Toriumi H, Kuang Y, Chen H, Fu ZF. The 
roles of chemokines in rabies virus infection: 
overexpression may not always be beneficial.  
J Virol. 2009;83(22):11808–11818.
 11. Wang Y, Lobigs M, Lee E, Müllbacher A. CD8+ 
T cells mediate recovery and immunopathol-
ogy in West Nile virus encephalitis. J Virol. 
2003;77(24):13323–13334.
 12. Furr SR, Marriott I. Viral CNS infections: role of 
glial pattern recognition receptors in neuroin-
flammation. Front Microbiol. 2012;3:201.
 13. Furr SR, Moerdyk-Schauwecker M, Grdzelishvili 
VZ, Marriott I. RIG-I mediates nonsegmented 
negative-sense RNA virus-induced inflammatory 
immune responses of primary human astrocytes. 
Glia. 2010;58(13):1620–1629.
 14. Pfefferkorn C, et al. Abortively infected astro-
cytes appear to represent the main source of 
interferon beta in the virus-infected brain.  
J Virol. 2015;90(4):2031–2038.
 15. Zhang Y, Barres BA. Astrocyte heterogeneity: an 
underappreciated topic in neurobiology. Curr 
Opin Neurobiol. 2010;20(5):588–594.
 16. Morga E, Faber C, Heuschling P. Regional hetero-
geneity of the astroglial immunoreactive pheno-
type: effect of lipopolysaccharide. J Neurosci Res. 
1999;57(6):941–952.
 17. Fitting S, Zou S, Chen W, Vo P, Hauser KF, Knapp 
PE. Regional heterogeneity and diversity in 
cytokine and chemokine production by astroglia: 
differential responses to HIV-1 Tat, gp120, and 
morphine revealed by multiplex analysis. J Pro-
teome Res. 2010;9(4):1795–1804.
 18. Cho H, Proll SC, Szretter KJ, Katze MG, Gale 
M, Diamond MS. Differential innate immune 
response programs in neuronal subtypes deter-
mine susceptibility to infection in the brain 
by positive-stranded RNA viruses. Nat Med. 
2013;19(4):458–464.
 19. Hart J, et al. West Nile virus neuroinvasive disease: 
neurological manifestations and prospective lon-
gitudinal outcomes. BMC Infect Dis. 2014;14:248.
 20. Shrestha B, Gottlieb D, Diamond MS. Infection 
and injury of neurons by West Nile encephalitis 
virus. J Virol. 2003;77(24):13203–13213.
 21. Durrant DM, Daniels BP, Klein RS. IL-1R1 signal-
ing regulates CXCL12-mediated T cell localiza-
tion and fate within the central nervous system 
during West Nile Virus encephalitis. J Immunol. 
2014;193(8):4095–4106.
 22. Tao J, et al. Deletion of astroglial Dicer causes 
non-cell-autonomous neuronal dysfunction and 
degeneration. J Neurosci. 2011;31(22):8306–8319.
 23. Niu W, et al. In vivo reprogramming of astrocytes 
to neuroblasts in the adult brain. Nat Cell Biol. 
2013;15(10):1164–1175.
 24. Howng SY, Huang Y, Ptáček L, Fu YH. Under-
standing the role of dicer in astrocyte develop-
ment. PLoS ONE. 2015;10(5):e0126667.
 25. Molumby MJ, Keeler AB, Weiner JA. Homophilic 
protocadherin cell-cell interactions promote den-
drite complexity. Cell Rep. 2016;15(5):1037–1050.
 26. Pinto AK, et al. Deficient IFN signaling 
by myeloid cells leads to MAVS-depen-
dent virus-induced sepsis. PLoS Pathog. 
2014;10(4):e1004086.
 27. Lazear HM, et al. Interferon-λ restricts 
West Nile virus neuroinvasion by tighten-
ing the blood-brain barrier. Sci Transl Med. 
2015;7(284):284ra59.
 28. Miner JJ, et al. The TAM receptor Mertk protects 
against neuroinvasive viral infection by main-
taining blood-brain barrier integrity. Nat Med. 
2015;21(12):1464–1472.
 29. Tedeschi B, Barrett JN, Keane RW. Astrocytes 
produce interferon that enhances the expression 
of H-2 antigens on a subpopulation of brain cells. 
J Cell Biol. 1986;102(6):2244–2253.
 30. Keller BC, et al. Resistance to alpha/beta 
interferon is a determinant of West Nile virus 
replication fitness and virulence. J Virol. 
2006;80(19):9424–9434.
 31. Klein RS, et al. Neuronal CXCL10 directs CD8+ 
T-cell recruitment and control of West Nile virus 
encephalitis. J Virol. 2005;79(17):11457–11466.
 32. Floris S, et al. Interferon-beta directly influences 
monocyte infiltration into the central nervous 
system. J Neuroimmunol. 2002;127(1-2):69–79.
 33. Bitsch A, et al. Interferon beta-1b modulates 
serum sVCAM-1 levels in primary progres-
sive multiple sclerosis. Acta Neurol Scand. 
2004;110(6):386–392.
 34. Calabresi PA, et al. Increases in soluble VCAM-1 
correlate with a decrease in MRI lesions in multi-
ple sclerosis treated with interferon beta-1b. Ann 
Neurol. 1997;41(5):669–674.
 35. Engelhardt B, Ransohoff RM. Capture, crawl, 
cross: the T cell code to breach the blood-brain 
barriers. Trends Immunol. 2012;33(12):579–589.
 36. Gimenez MA, Sim JE, Russell JH. TNFR1-depen-
dent VCAM-1 expression by astrocytes exposes 
the CNS to destructive inflammation. J Neuroim-
munol. 2004;151(1–2):116–125.
Downloaded from http://www.jci.org on April 17, 2017.   https://doi.org/10.1172/JCI88720
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
8 5 6 jci.org   Volume 127   Number 3   March 2017
 37. Archambault AS, Sim J, McCandless EE, Klein 
RS, Russell JH. Region-specific regulation of 
inflammation and pathogenesis in experimental 
autoimmune encephalomyelitis. J Neuroimmunol. 
2006;181(1–2):122–132.
 38. Getts DR, et al. Targeted blockade in lethal West 
Nile virus encephalitis indicates a crucial role 
for very late antigen (VLA)-4-dependent recruit-
ment of nitric oxide-producing macrophages. 
 J Neuroinflammation. 2012;9:246.
 39. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, 
Goverman JM. Differential regulation of central 
nervous system autoimmunity by T(H)1 and 
T(H)17 cells. Nat Med. 2008;14(3):337–342.
 40. Rosato PC, Leib DA. Neuronal interferon sig-
naling is required for protection against herpes 
simplex virus replication and pathogenesis. PLoS 
Pathog. 2015;11(7):e1005028.
 41. Farmer JR, Altschaefl KM, O’Shea KS, Miller DJ. 
Activation of the type I interferon pathway is 
enhanced in response to human neuronal differ-
entiation. PLoS ONE. 2013;8(3):e58813.
 42. Schultz KL, Vernon PS, Griffin DE. Differenti-
ation of neurons restricts Arbovirus replication 
and increases expression of the alpha isoform of 
IRF-7. J Virol. 2015;89(1):48–60.
 43. Molofsky AV, et al. Astrocyte-encoded positional 
cues maintain sensorimotor circuit integrity. 
Nature. 2014;509(7499):189–194.
 44. Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, 
McKhann GM, Goldman JE. Phenotypic hetero-
geneity and plasticity of isocortical and hippo-
campal astrocytes in the human brain. J Neurosci. 
2014;34(6):2285–2298.
 45. Durrant DM, Robinette ML, Klein RS. IL-1R1 is 
required for dendritic cell-mediated T cell reac-
tivation within the CNS during West Nile virus 
encephalitis. J Exp Med. 2013;210(3):503–516.
 46. McCandless EE, Budde M, Lees JR, Dorsey D, 
Lyng E, Klein RS. IL-1R signaling within the cen-
tral nervous system regulates CXCL12 expression 
at the blood-brain barrier and disease severity 
during experimental autoimmune encephalomy-
elitis. J Immunol. 2009;183(1):613–620.
 47. Samuel MA, Wang H, Siddharthan V, Morrey JD, 
Diamond MS. Axonal transport mediates West 
Nile virus entry into the central nervous system 
and induces acute flaccid paralysis. Proc Natl 
Acad Sci USA. 2007;104(43):17140–17145.
 48. Maximova OA, Bernbaum JG, Pletnev AG. West 
Nile virus spreads transsynaptically within the 
pathways of motor control: Anatomical and ultra-
structural mapping of neuronal virus infection 
in the primate central nervous system. PLoS Negl 
Trop Dis. 2016;10(9):e0004980.
 49. Guarda G, et al. Type I interferon inhibits inter-
leukin-1 production and inflammasome activa-
tion. Immunity. 2011;34(2):213–223.
 50. Inoue M, Shinohara ML. The role of interferon-β 
in the treatment of multiple sclerosis and exper-
imental autoimmune encephalomyelitis - in the 
perspective of inflammasomes. Immunology. 
2013;139(1):11–18.
 51. Moynagh PN. The interleukin-1 signalling path-
way in astrocytes: a key contributor to inflamma-
tion in the brain. J Anat. 2005;207(3):265–269.
 52. An Y, Chen Q, Quan N. Interleukin-1 exerts dis-
tinct actions on different cell types of the brain in 
vitro. J Inflamm Res. 2011;2011(4):11–20.
 53. Campbell JH, et al. Anti-α4 antibody treatment 
blocks virus traffic to the brain and gut early, and 
stabilizes CNS injury late in infection. PLoS Pat-
hog. 2014;10(12):e1004533.
 54. Shrestha B, Diamond MS. Role of CD8+ T cells 
in control of West Nile virus infection. J Virol. 
2004;78(15):8312–8321.
 55. Szretter KJ, et al. 2’-O methylation of the 
viral mRNA cap by West Nile virus evades 
ifit1-dependent and -independent mecha-
nisms of host restriction in vivo. PLoS Pathog. 
2012;8(5):e1002698.
 56. Ramirez P, et al. BIO5192, a small mole-
cule inhibitor of VLA-4, mobilizes hema-
topoietic stem and progenitor cells. Blood. 
2009;114(7):1340–1343.
 57. Ali M, Safriel Y, Sohi J, Llave A, Weathers S. 
West Nile virus infection: MR imaging findings 
in the nervous system. AJNR Am J Neuroradiol. 
2005;26(2):289–297.
 58. Wang HY, Matsui M, Saida T. Immunological 
disturbances in the central nervous system linked 
to MRI findings in multiple sclerosis. J Neuroim-
munol. 2002;125(1–2):149–154.
 59. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, 
Jolesz FA, Weiner HL. Changes in activated T cells 
in the blood correlate with disease activity in mul-
tiple sclerosis. Arch Neurol. 2000;57(8):1183–1189.
 60. Cramer SP, Modvig S, Simonsen HJ, Frederiksen JL, 
Larsson HB. Permeability of the blood-brain barrier 
predicts conversion from optic neuritis to multiple 
sclerosis. Brain. 2015;138(Pt 9):2571–2583.
 61. Rothhammer V, et al. α4-integrins control viral 
meningoencephalitis through differential 
recruitment of T helper cell subsets. Acta Neuro-
pathol Commun. 2014;2:27.
 62. Le Bon A, et al. Direct stimulation of T cells by type 
I IFN enhances the CD8+ T cell response during 
cross-priming. J Immunol. 2006;176(8):4682–4689.
 63. Engle MJ, Diamond MS. Antibody prophylaxis 
and therapy against West Nile virus infection in 
wild-type and immunodeficient mice. J Virol. 
2003;77(24):12941–12949.
 64. Ebel GD, et al. Partial genetic characterization of 
West Nile virus strains, New York State, 2000. 
Emerging Infect Dis. 2001;7(4):650–653.
 65. Beasley DW, Li L, Suderman MT, Barrett AD. 
Mouse neuroinvasive phenotype of West Nile 
virus strains varies depending upon virus geno-
type. Virology. 2002;296(1):17–23.
 66. Brien JD, Lazear HM, Diamond MS. Propa-
gation, quantification, detection, and storage 
of West Nile virus. Curr Protoc Microbiol. 
2013;31:15D.3.1–15D.3.18.
 67. Lu ZH, et al. The myeloid-binding peptide adenovi-
ral vector enables multi-organ vascular endothelial 
gene targeting. Lab Invest. 2014;94(8):881–892.
 68. Leone DR, et al. An assessment of the mechanis-
tic differences between two integrin alpha 4 beta 
1 inhibitors, the monoclonal antibody TA-2 and 
the small molecule BIO5192, in rat experimental 
autoimmune encephalomyelitis. J Pharmacol Exp 
Ther. 2003;305(3):1150–1162.
Downloaded from http://www.jci.org on April 17, 2017.   https://doi.org/10.1172/JCI88720
